References

mimmun

Медицинская иммунология

Medical Immunology (Russia)

1563-06252313-741X

SPb RAACI

10.15789/1563-0625-2007-1-15-34

mimmun-116

Research Article

ОБЗОРЫ

REVIEWS

АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ

ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES

Маслянский

А. Л.

Masliansky

A. L.

к.м.н., зав. отделением аллергологии и иммунологии Северо-Западного Медицинского Окружного Центра

Санкт-Петербург, В.О., Съездовская линия, д. 13/15. Тел.: (812) 323-21-49

Мазуров

В. И.

Mazurov

V. I.

Зоткин

Е. Г.

Zotkin

E. G.

Иливанова

Е. П.

Ilivanova

E. P.

Тотолян

Арег А.

Totolian

Areg A.

Северо-Западный федеральный медицинский центрРоссия

Санкт-Петербургская медицинская академия последипломного образованияРоссия

Ленинградская областная клиническая больница, Санкт-ПетербургРоссия

Санкт-Петербургский Государственный медицинский университет им. акад. И.П. ПавловаРоссия

2007

15072014

911534

2014

Маслянский А.Л., Мазуров В.И., Зоткин Е.Г., Иливанова Е.П., Тотолян А.А.

Masliansky A.L., Mazurov V.I., Zotkin E.G., Ilivanova E.P., Totolian A.A.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.mimmun.ru/mimmun/article/view/116

Резюме. В настоящее время накоплен значительный объем экспериментальных и клинических данных, позволяющих по-новому взглянуть на роль В-клеток в формировании иммунного ответа при аутоиммунных заболеваниях. В связи с этим разрабатываются новые терапевтические подходы, базирующиеся на использовании анти-В-клеточных препаратов в лечении данной патологии. Высокая эффективность ритуксимаба, химерного моноклонального антитела к CD20 маркеру, при его использовании в комбинации с другими иммуносупрессивными препаратами, доказана при лечении больных ревматоидным артритом, резистентным к стандартной базисной терапии. В литературе представлено большое число описаний клинических случаев и небольших открытых исследований успешного применения ритуксимаба при широком круге других, нежели РА, аутоиммунных заболеваний человека. Хотя в настоящее время эти данные следует рассматривать как предварительные,они свидетельствуют о возможной роли ритуксимаба в лечении различных заболеваний, что существенно расширяет спектр терапевтических возможностей. Не вызывает сомнений необходимость проведения дальнейших исследований с целью подтверждения клинической эффективности ритуксимаба при различных нозологических формах аутоиммунных заболеваний, определения оптимальных режимов дозирования и алгоритма его использования в лечении таких больных.

Abstract. Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. As pathogenic elements in the development of autoimmune diseases, B-cells have become the focus of new therapeutics. Based on the published data, rituximab, a chimeric monoclonal antibody to CD20, when used in combination with other agents (i.e., cyclophosphamide or methotrexate), appears to be a reasonable treatment option for refractory RA. There are now numerous case reports and small openlabel series using rituximab in many autoimmune diseases, others then RA. While these data must be interpreted with caution, they suggest that rituximab may be a promising addition to the therapeutic armamentarium in these diseases. However, additional controlled trials need to be conducted to confirm clinical efficacy, further define optimal dosage, response rates, comparative long-term efficacy, and treatment algorithm for rituximab in these patients.

мабтераВ-клеточная терапияаутоиммунные заболеванияВ-лимфоцитыритуксимабCD20-антиген

mabteraanti-В-cell therapyautoimmune diseasesВ-lymphocytesrituximabCD20

References1

Baecklund E., Askling J., Rosenquist R., Ekbom A., Klareskog L. Rheumatoid arthritis and malignant lymphomas // Curr. Opin. Rheumatol. – 2004. – Vol. 1, N 3. – P. 254-261.

Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., Olsson H., Jacobsson L.T. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas // Ann. Rheum. Dis. – 2005. – Vol. 64, N 5. – P. 699-703.

Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., Gromnica-Ihle E., Antoni C., Herzer P., Kekow J., Schneider M., Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents // Arthritis Rheum. – 2005. – Vol. 52, N 11. – P. 3403-3412.

Marmont A.M. Stem cell transplantation for severe autoimmune diseases: progress and problems // Haematologica. – 1998. – Vol. 83, N 8. – P. 733-743.

Lorenz H.M., Herrmann M., Kalden J.R. The pathogenesis of autoimmune diseases // Scand. J. Clin. Lab. Invest. Suppl. – 2001. – Vol. 235. – P. 16-26.

Panayi G.S., Corrigall V.M., Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts // Rheum. Dis. Clin. North. Am. – 2001. – Vol. 27, N 2. – P. 317-334.

Weyand C.M., Bryl E., Goronzy J.J. The role of T-cells in rheumatoid arthritis // Arch. Immunol. Ther. Exp. (Warsz.). – 2000. – Vol. 48, N 5. – P. 429-35.

Kinne R.W., Brauer R., Stuhlmuller B., Palombo-Kinne E., Burmester G.R. Macrophages in rheumatoid arthritis // Arthritis Res. – 2000. – Vol. 2, N 3. – P. 189-202.

Imamura F., Aono H., Hasunuma T., Sumida T., Tateishi H., Maruo S., Nishioka K. Monoclonal expansion of synoviocytes in rheumatoid arthritis // Arthritis Rheum. – 1998. – Vol. 41, N 11. – P. 1979-1986.

Isaacs J.D., Burrows N., Wing M., Keogan M.T., Rebello P.R., Watts R.A., Pye R.J., Norris P., Hazelman B.L., Hale G., Waldmann H. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease // Clin. Exp. Immunol. – 1997. – Vol. 110, N 2. – P. 158-166.

Matteson E.L., Yocum D.E., St Clair E.W., Achkar A.A., Thakor M.S., Jacobs M.R., Hays A.E., Heitman C.K., Johnston J.M. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection // Arthritis Rheum. – 1995. – Vol. 38, N 9. – P. 1187-1193.

Lee D.M., Friend D.S., Gurish M.F., Benoist C., Mathis D., Brenner M.B. Mast cells: a cellular link between autoantibodies and inflammatory arthritis // Science. – 2002. – Vol. 297, N 5587. – P. 1689-1692.

Lovgren T., Eloranta M.L., Bave U., Alm G.V., Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG // Arthritis Rheum. – 2004. – Vol. 50, N 6. – P. 1861-1872.

Martin F., Chan A.C. B-cell immunobiology in disease: evolving concepts from the clinic // Annu. Rev. Immunol. – 2006. – Vol. 24. – P. 467-496.

Vallin H., Perers A., Alm G.V., Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus // J. Immunol. – 1999. – Vol. 163, N 11. – P. 6306-6313.

Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibodyindependent role for B cells in murine lupus // J. Exp. Med. – 1999. – Vol. 189, N 10. – P. 1639-1648.

Wong F.S., Wen L., Tang M., Ramanathan M., Visintin I., Daugherty J., Hannum L.G., Janeway Jr. C.A., Shlomchik M.J. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse // Diabetes. – 2004. – Vol. 53, N 10. – P. 2581-2587.

O’Neill S.K., Shlomchik M.J., Glant T.T., Cao Y., Doodes P.D., Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis // J. Immunol. – 2005. – Vol. 174, N 6. – P. 3781-3788.

Soderstrom N.A.B. Organization of the invading lymphoid tissue in human lymphoid thyroiditis // Scand. J. Immunol. – 1974. – Vol. 3, N 3. – P. 295-301.

Prineas J.W. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord // Science. – 1979. – Vol. 203, N 4385. – P. 1123-1125.

Stott D.I., Hiepe F., Hummel M., Steinhauser G., Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren’s syndrome // J. Clin. Invest. – 1998. – Vol. 102, N 5. – P. 938-946.

Lorenz R.G., Chaplin D.D., McDonald K.G., McDonough J.S., Newberry R.D. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function // J. Immunol. – 2003. – Vol. 170, N 11. – P. 5475-5482.

Ansel K.M., Ngo V.N., Hyman P.L., Luther S.A., Forster R., Sedgwick J.D., Browning J.L., Lipp M., Cyster J.G. A chemokine-driven positive feedback loop organizes lymphoid follicles // Nature. – 2000. – Vol. 406, N 6793. – P. 309-314.

Mariathasan S., Matsumoto M., Baranyay F., Nahm M.H., Kanagawa O., Chaplin D.D. Absence of lymph nodes in lymphotoxin-alpha (LT alpha)-deficient mice is due to abnormal organ development, not defective lymphocyte migration // J. Inflamm. – 1995. – Vol. 45, N 1. – P. 72-78.

Matsumoto M., Mariathasan S., Nahm M.H., Baranyay F., Peschon J.J., Chaplin D.D. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers // Science. – 1996. – Vol. 271, N 5253. – P. 1289-1291.

Ngo V.N., Cornall R.J., Cyster J.G. Splenic T-zone development is B cell dependent // J. Exp. Med. – 2001. – Vol. 194, N 11. – P. 1649-1660.

Kurt-Jones E.A., Liano D., HayGlass K.A., Benacerraf B., Sy M.S., Abbas A.K. The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice // J. Immunol. – 1988. – Vol. 140, N 11. – P. 3773-3778.

Chan O., Shlomchik M.J. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice // J. Immunol. – 1998. – Vol. 160, N 1. – P. 51-59.

Takemura S., Klimiuk P.A., Braun A., Goronzy J.J., Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent // J. Immunol. – 2001. – Vol. 167, N 8. – P. 4710-4718.

Olson T.S., Bamias G., Naganuma M., Rivera-Nieves J., Burcin T.L., Ross W., Morris M.A., Pizarro T.T., Ernst P.B., Cominelli F., Ley K. Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease // J. Clin Invest. – 2004. – Vol. 114, N 3. – P. 389-398.

Yu S., Maiti P.K., Dyson M., Jain R., Braley-Mullen H. B cell-deficient NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis // J. Exp. Med. – 2006. – Vol. 203, N 2. – P. 349-358.

Pistoia V. Production of cytokines by human B cells in health and disease // Immunol. Today. – 1997. – Vol. 18, N 7. – P. 343-350.

Mewar D., Wilson A.G. Autoantibodies in rheumatoid arthritis: a review // Biomed. Pharmacother. – 2006. – Vol. 60, N 10. – P. 648-655.

Nielen M.M., van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., Habibuw M.R., Vandenbroucke J.P., Dijkmans B.A. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors // Arthritis Rheum. – 2004. – Vol. 50, N 2. – P. 380-386.

Binder M., Otto F., Mertelsmann R., Veelken H., Trepel M. The epitope recognized by rituximab // Blood. – 2006. – Vol. 108, N 6. – P. 1975-1978.

Protheroe A., Edwards J.C., Simmons A., Maclennan K., Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin’s lymphoma // Rheumatology (Oxford). – 1999. – Vol. 38, N 11. – P. 1150-1152.

Leandro M.J., Edwards J.C., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B-lymphocyte depletion // Ann. Rheum. Dis. – 2002. – Vol. 61, N 10. – P. 883-888.

Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis // N. Engl. J. Med. – 2004. – Vol. 350, N 25. – P. 2572-2581.

Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., Racewicz A.J., van Vollenhoven R.F., Li N.F., Agarwal S., Hessey E.W., Shaw T.M. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial // Arthritis Rheum. – 2006. – Vol. 54, N 5. – P. 1390-1400.

Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., Keystone E.C., Loveless J.E., Burmester G.R., Cravets M.W., Hessey E.W., Shaw T., Totoritis M.C. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks // Arthritis Rheum. – 2006. – Vol. 54, N 9. – P. 2793-2806.

Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients // Rheumatology (Oxford). – 2005. – Vol. 44, N 12. – P. 1542-1545.

Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus // Arthritis Rheum. – 2004. – Vol. 50, N 11. – P. 3580-3590.

Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., Sloand J.A., Rosenblatt J., Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab // Arthritis Rheum. – 2004. – Vol. 50, N 8. – P. 2580-2589.

Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., Vissink A., Kallenberg C.G., Bootsma H. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study // Arthritis Rheum. – 2005. – Vol. 52, N 9. – P. 2740-2750.

Keogh K.A., Wylam M.E., Stone J.H., Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis // Arthritis Rheum. – 2005. – Vol. 52, N 1. – P. 262-268.

Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study // Arthritis Rheum. – 2005. – Vol. 52, N 2. – P. 601-607.

Schmidt E., Hunzelmann N., Zillikens D., Brocker E.B., Goebeler M. Rituximab in refractory autoimmune bullous diseases // Clin. Exp. Dermatol. – 2006. – Vol. 31, N 4. – P. 503-508.

Hoffman P.C. Immune hemolytic anemia – selected topics // Hematology Am. Soc. Hematol. Educ. Program. – 2006. – P. 13-18.

Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., Fraser G.A., Lim W., Kelton J.G. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura // Ann. Intern. Med. – 2007. – Vol. 146, N 1. – P. 25-33.

Bay A., Oner A.F., Uner A., Dogan M. Use of rituximab in chronic childhood immune thrombocytopenic purpura // Pediatr. Int. – 2006. – Vol. 48, N 5. – P. 514-516.

Kavanaugh A.F. B cell targeted therapies: safety considerations // J. Rheumatol. Suppl. – 2006. – Vol. 77. – P. 18-23.

De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells // Arthritis Rheum. – 2002. – Vol. 46, N 8. – P. 2029-2033.

Kneitz C., Wilhelm M., Tony H.P. Improvement of refractory rheumatoid arthritis after depletion of B cells // Scand. J. Rheumatol. – 2004. – Vol. 33, N 2. – P. 82-86.

Moore J., Ma D., Will R., Cannell P., Handel M., Milliken S. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation // Bone Marrow Transplant. – 2004. – Vol. 34, N 3. – P. 241-247.

Roll P., Palanichamy A., Kneitz C., Dorner T., Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis // Arthritis Rheum. – 2006. – Vol. 54, N 8. – P. 2377-2386.

Petschner F., Walker U.A., Schmitt-Graff A., Uhl M., Peter H.H. «Catastrophic systemic lupus erythematosus» with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/ rutuximab // Dtsch. Med. Wochenschr. – 2001. – Vol. 126, N 37. – P. 998-1001.

Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P., Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus // Br. J. Haematol. – 2002. – Vol. 116, N 2. – P. 465-467.

Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., Looney R.J. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus // Arthritis Rheum. – 2003. – Vol. 48, N 2. – P. 455-459.

Weide R., Heymanns J., Pandorf A., Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy // Lupus. – 2003. – Vol. 12, N 10. – P. 779-782.

Tokunaga M., Fujii K., Saito K., Nakayamada S., Tsujimura S., Nawata M., Tanaka Y. Downregulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab // Rheumatology (Oxford). – 2005. – Vol. 44, N 2. – P. 176-182.

Edelbauer M., Jungraithmayr T., Zimmerhackl L.B. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report // Pediatr. Nephrol. – 2005. – Vol. 20, N 6. – P. 811-813.

van Vollenhoven R.F., Gunnarsson I., Welin-Henriksson E., Sundelin B., Osterborg A., Jacobson S.H., Klareskog L. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-D20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone // Scand. J. Rheumatol. – 2004. – Vol. 33, N 6. – P. 423-427.

Lambotte O., Durbach A., Kotb R., Ferlicot S., Delfraissy J.F., Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis // Clin Nephrol. – 2005. – Vol. 64, N 1. – P. 73-77.

Sabugo F., Llanos C., Soto L., Gutierrez J., Cuchacovich M. Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case // Rev. Med. Chil. – 2005. – Vol. 133, N 6. – P. 681-684.

Van den Bergh B., Selleslag D., Boelaert J.R., Matthys E.G., Schurgers M., Vandecasteele S., De Vriese A. Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature // Acta Clin. Belg. – 2005. – Vol. 60, N 2. – P. 102-105.

Marks S.D., Patey S., Brogan P.A., Hasson N., Pilkington C., Woo P., Tullus K. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus // Arthritis Rheum. – 2005. – Vol. 52, N 10. – P. 3168-3174.

Armstrong D., Wright S., McVeigh C., Finch M. Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman-Sacks endocarditis: a case for antibiotic prophylaxis? // Clin. Rheumatol. – 2006. – Vol. 25, N 4. – P. 583-584.

Lehembre S., Macario-Barrel A., Musette P., Carvalho P., Joly P. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus // Ann. Dermatol. Venereol. – 2006. – Vol. 133, N 1. – P. 53-55.

Lim S.W., Gillis D., Smith W., Hissaria P., Greville H., Peh C.A. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports // Intern. Med. J. – 2006. – Vol. 36, N 4. – P. 260-262.

Gomard-Mennesson E., Ruivard M., Koenig M., Woods A., Magy N., Ninet J., Rousset H., Salles G., Broussolle C., Seve P. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases // Lupus. – 2006. – Vol. 15, N 4. – P. 223-231.

Willems M., Haddad E., Niaudet P., Kone-Paut I., Bensman A., Cochat P., Deschenes G., Fakhouri F., Leblanc T., Llanas B., Loirat C., Pillet P., Ranchin B., Salomon R., Ulinski T., Bader-Meunier B. Rituximab therapy for childhood-onset systemic lupus erythematosus // J. Pediatr. – 2006. – Vol. 148, N 5. – P. 623-627.

Jansson A.F., U. Wintergerst, E.D. Renner, B.H. Belohradsky. Rituximab-induced long-term remission in two children with SLE // Eur. J. Pediatr. – 2007. – Vol. 166, N 2. – P. 177-181.

Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and retreatment // Arthritis Rheum. – 2006. – Vol. 54, N 9. – P. 2970-2982.

Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., Tsujimura S., Nawata M., Iwata S., Azuma T., Mimori T., Tanaka Y. Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system // Ann. Rheum. Dis., 2006.

Kotani T., Takeuchi T., Kawasaki Y., Hirano S., Tabushi Y., Kagitani M., Makino S., Hanafusa T. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus // Lupus. – 2006. – Vol. 15, N 10. – P. 683-685.

Specks U., Fervenza F.C., McDonald T.J., Hogan M.C. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy // Arthritis Rheum. – 2001. – Vol. 44, N 12. – P. 2836-2840.

Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab // J. Intern. Med. – 2005. – Vol. 257, N 6. – P. 540-548.

Omdal R., Wildhagen K., Hansen T., Gunnarsson R., Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response // Scand. J. Rheumatol. – 2005. – Vol. 34, N 3. – P. 229-232.

Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial // Am. J. Respir. Crit. Care Med. – 2006. – Vol. 173, N 2. – P. 180-187.

Aries P.M., Hellmich B., Voswinkel J., Both M., Nolle B., Holl-Ulrich K., Lamprecht P., Gross W.L. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations // Ann. Rheum. Dis. – 2006. – Vol. 65, N 7. – P. 853-858.

Clatworthy M.R., Jayne D.R. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab // Am. J. Kidney Dis. – 2006. – Vol. 47, N 4. – P. 680-682.

Stasi R., Stipa E., Del Poeta G., Amadori S., Newland A.C., Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibodyassociated vasculitis treated with rituximab // Rheumatology (Oxford). – 2006. – Vol. 45, N 11. – P. 1432-1436.

Tektonidou M.G., Skopouli F.N. Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener’s granulomatosis // Clin. Exp. Rheumatol. – 2006. – Vol. 24, N 2, Suppl. 41. – P. S103.

Koukoulaki M., Smith K.G., Jayne D.R. Rituximab in Churg-Strauss syndrome // Ann. Rheum. Dis. – 2006. – Vol. 65, N 4. – P. 557-559.

Somer B.G., Tsai D.E., Downs L., Weinstein B., Schuster S.J. Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma // Arthritis Rheum. – 2003. – Vol. 49, N 3. – P. 394-398.

Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., Candon S., Leguern V., Aouba A., Jean S., Gottenberg J.E., Mariette X. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome // Ann. Rheum. Dis., 2006.

Chiappetta N., Steier J., Gruber B. Rituximab in the treatment of refractory dermatomyositis // J. Clin. Rheumatol. – 2005. – Vol. 11, N 5. – P. 264-266.

Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis // J. Rheumatol. – 2006. – Vol. 33, N 5. – P. 1021-1026.

Zaja F., Russo D., Fuga G., Patriarca F., Ermacora A., Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia // Haematologica. – 1999. – Vol. 84, N 12. – P. 1157-1158.

Arzoo K., Sadeghi S., Liebman H.A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) // Ann. Rheum. Dis. – 2002. – Vol. 61, N 10. – P. 922-924.

Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 // Blood. – 2003. – Vol. 101, N 10. – P. 3818-3826.

Lamprecht P., Lerin-Lozano C., Merz H., Dennin R.H., Gause A., Voswinkel J., Peters S.O., Gutzeit O., Arlt A.C., Solbach W., Gross W.L. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis // Ann. Rheum. Dis. – 2003. – Vol. 62, N 12. – P. 1230-1233.

Roccatello D., Baldovino S., Rossi D., Mansouri M., Naretto C., Gennaro M., Cavallo R., Alpa M., Costanzo P., Giachino O., Mazzucco G., Sena L.M. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis // Nephrol. Dial. Transplant. – 2004. – Vol. 19, N 12. – P. 3054-3061.

Catuogno M., Rezai S., Priori R., Magrini L., Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia // Rheumatology (Oxford). – 2005. – Vol. 44, N 3. – P. 406.

Kay J., McCluskey R.T. Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency // N. Engl. J. Med. – 2005. – Vol. 353, N 15. – P. 1605-1613.

Cai F.Z., Ahern M., Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab // J. Rheumatol. – 2006. – Vol. 33, N 6. – P. 1197-1198.

Pekow J., Chung R.T. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab // J. Clin. Gastroenterol. – 2006. – Vol. 40, N 5. – P. 450.

Basse G., Ribes D., Kamar N., Mehrenberger M., Sallusto F., Esposito L., Guitard J., Lavayssiere L., Oksman F., Durand D., Rostaing L. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients // Transplant. Proc. – 2006. – Vol. 38, N 7. – P. 2308-2310.

Cohen H., Green S., Jones S., Amos N., William B.D. Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia // Rheumatology (Oxford), 2006.

100

Rubenstein E., Arkfeld D.G., Metyas S., Shinada S., Ehresmann S., Liebman H.A. Rituximab treatment for resistant antiphospholipid syndrome // J. Rheumatol. – 2006. – Vol. 33, N 2. – P. 355-357.

101

Anandacoomarasamy A., Gibson J., McGill N. «Cure» of life-threatening antiphospholipid syndrome with rituximab // Intern. Med. J. – 2006. – Vol. 36, N 7. – P. 474-475.

102

Ames P.R., Tommasino C., Fossati G., Scenna G., Brancaccio V., Ferrara F. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome // Ann. Hematol., 2006.

103

Ahn E.R., Lander G., Bidot C.J., Jy W., Ahn Y.S. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy // Am. J. Hematol. – 2005. – Vol. 78, N 2. – P. 127-129.

104

Hongeng S., Tardtong P., Worapongpaiboon S., Ungkanont A., Jootar S. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab // Bone Marrow Transplant. – 2002. – Vol. 29, N 10. – P. 871-872.

105

Gupta N., Kavuru S., Patel D., Janson D., Driscoll N., Ahmed S., Rai K.R. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia // Leukemia. – 2002. – Vol. 16, N 10. – P. 2092-2095.

106

Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., Jankovic M., Pierani P., De Stefano P., Bonora M.R., Locatelli F. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children // Blood. – 2003. – Vol. 101, N 10. – P. 3857-3861.

107

Motto D.G., Williams J.A., Boxer L.A. Rituximab for refractory childhood autoimmune hemolytic anemia // Isr. Med. Assoc. J. – 2002. – Vol. 4, N 11. – P. 1006-1008.

108

Gottardo N.G., Baker D.L., Willis F.R. Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab // Pediatr. Hematol. Oncol. – 2003. – Vol. 20, N 7. – P. 557-561.

109

Endo T., Nakao S., Koizumi K., Nishio M., Fujimoto K., Sakai T., Kumano K., Obara M., Koike T. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient // Ann. Hematol. – 2004. – Vol. 83, N 2. – P. 114-116.

110

Shanafelt T.D., Madueme H.L., Wolf R.C., Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome // Mayo Clin. Proc. – 2003. – Vol. 78, N 11. – P. 1340-1346.

111

Raj A., Bertolone S., Cheerva A. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease // J. Pediatr. Hematol. Oncol. – 2004. – Vol. 26, N 5. – P. 312-314.

112

Erdozain J.G., Ruiz-Irastorza G., Egurbide M.V., Aguirre C. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome // Haematologica. – 2004. – Vol. 89, N 9. – P. ECR34.

113

Narat S., Gandla J., Hoffbrand A.V., Hughes R.G., Mehta A.B. Rituximab in the treatment of refractory autoimmune cytopenias in adults // Haematologica. – 2005. – Vol. 90, N 9. – P. 1273-1274.

114

van Daalen S.T., van Dijken P.J., Tamminga R.Y., Brons P.P. Rituximab instead of splenectomy in 4 children with chronic or refractory autoimmune haemolytic anaemia // Ned. Tijdschr. Geneeskd. – 2005. – Vol. 149, N 42. – P. 2350-2354.

115

Nishida H., Murase T., Ueno H., Park J.W., Yano T., Ikeda Y. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia // Leuk. Res. – 2006. – Vol. 30, N 12. – P. 1589-1590.

116

Pamuk G.E., Turgut B., Demir M., Tezcan F., Vural O. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia // Am. J. Hematol. – 2006. – Vol. 81, N 8. – P. 631- 633.

117

Saleh M.N., Gutheil J., Moore M., Bunch P.W., Butler J., Kunkel L., Grillo-Lopez A.J., LoBuglio A.F. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia // Semin. Oncol. – 2000. – Vol. 27, N 6, Suppl. 12. – P. 99-103.

118

Shvidel L., Klepfish A., Berrebi A. Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with lowgrade non-Hodgkin’s lymphoma // Am. J. Hematol. – 2001. – Vol. 67, N 3. – P. 213-214.

119

Faurschou M., Hasselbalch H.C., Nielsen O.J. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia // Eur. J. Haematol. – 2001. – Vol. 66, N 6. – P. 408-411.

120

Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura // Blood. – 2001. – Vol. 98, N 4. – P. 952-957.

121

Abdel-Raheem M.M., Potti A., Kobrinsky N. Severe Evans’s syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody // Ann. Hematol. – 2001. – Vol. 80, N 9. – P. 543-545.

122

Zaja F., Iacona I., Masolini P., Russo D., Sperotto A., Prosdocimo S., Patriarca F., de Vita S., Regazzi M., Baccarani M., Fanin R. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia // Haematologica. – 2002. – Vol. 87, N 2. – P. 189-195.

123

Delgado J., Bustos J.G., Jimenez-Yuste V., Hernandez-Navarro F. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura // Haematologica. – 2002. – Vol. 87, N 2. – P. 215-216.

124

Cohen Y., Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab // Hematol. J. – 2002. – Vol. 3, N 1. – P. 61-62.

125

Meo P., Stipa E., La Presa M., Bianchi M., Di Giulio C., Stasi R., Amadori S. Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study // Recenti Prog. Med. – 2002. – Vol. 93, N 7-8. – P. 421-427.

126

Giagounidis A.A., Anhuf J., Schneider P., Germing U., Sohngen D., Quabeck K., Aul C. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study // Eur. J. Haematol. – 2002. – Vol. 69, N 2. – P. 95-100.

127

D’Arena G., Luigiavigliotti M., Coccaro M., Iodice G., Tartarone A., Matera R., Di Renzo N. Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximab // Leuk. Lymphoma. – 2003. – Vol. 44, N 3. – P. 561-562.

128

Riksen N.P., Keuning J.J., Vreugdenhil G. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura // Neth. J. Med. – 2003. – Vol. 61, N 7. – P. 262-265.

129

Bengtson K.L., Skinner M.A., Ware R.E. Successful use of anti-CD20 (rituximab) in severe, lifethreatening childhood immune thrombocytopenic purpura // J. Pediatr. – 2003. – Vol. 143, N 5. – P. 670-673.

130

Thude H., Gruhn B., Werner U., Schorner U., Hafer R., Zintl F., Barz D. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis // Acta Haematol. – 2004. – Vol. 111, N 4. – P. 221-224.

131

Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M.A., Leonard J.P., Amadori S., Bussel J.B. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura // Br. J. Haematol. – 2004. – Vol. 125, N 2. – P. 232-239.

132

Pusiol A., Cesaro S., Nocerino A., Picco G., Zanesco L., Bisogno G. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia // Eur. J. Pediatr. – 2004. – Vol. 163, N 6. – P. 305-307.

133

Koulova L., Alexandrescu D., Dutcher J.P., O’Boyle K.P., Eapen S., Wiernik P.H. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases // Am. J. Hematol. – 2005. – Vol. 78, N 1. – P. 49-54.

134

Tanai C., Iki S., Nakahara F., Iijima K., Usuki K., Kuwana M., Urabe A. Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura // Rinsho Ketsueki. – 2004. – Vol. 45, N 11. – P. 1181-1186.

135

Lalayanni C., Stavroyianni N., Saloum R., Tsompanakou A., Anagnostopoulos A. Rituximab is effective for selected patients with chronic steroidrefractory immune thrombocytopenic purpura // Hematology. – 2004. – Vol. 9, N 4. – P. 287-289.

136

Taube T., Schmid H., Reinhard H., von Stackelberg A., Overberg U.S. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood // Haematologica. – 2005. – Vol. 90, N 2. – P. 281-283.

137

Braendstrup P., Bjerrum O.W., Nielsen O.J., Jensen B.A., Clausen N.T., Hansen P.B., Andersen I., Schmidt K., Andersen T.M., Peterslund N.A., Birgens H.S., Plesner T., Pedersen B.B., Hasselbalch H.C. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura // Am. J. Hematol. – 2005. – Vol. 78, N 4. – P. 275-280.

138

Moschovi M., Trimis G., Pergantou H., Platokouki H., Vrachnou E., Tzortzatou-Stathopoulou F. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura // J. Paediatr. Child Health. – 2005. – Vol. 41, N 7. – P. 384-386.

139

Carbone J., Escudero A., Mayayo M., Ballesteros M., Perez-Corral A., Sanchez-Ramon S., Sarmiento E., Micheloud D., Fernandez-Cruz E. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency. // Ann. N. Y. Acad. Sci. – 2005. – Vol. 1051. – P. 666-671.

140

Bennett C.M., Rogers Z.R., Kinnamon D.D., Bussel J.B., Mahoney D.H., Abshire T.C., Sawaf H., Moore T.B., Loh M.L., Glader B.E., McCarthy M.C., Mueller B.U., Olson T.A., Lorenzana A.N., Mentzer W.C., Buchanan G.R., Feldman H.A., Neufeld E.J. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura // Blood. – 2006. – Vol. 107, N 7. – P. 2639-2642.

141

Ojeda-Uribe M., Brunot A., Issler M. Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case // Rev. Med. Chil. – 2005. – Vol. 133, N 11. – P. 1349-1354.

142

Penalver F.J., Jimenez-Yuste V., Almagro M., Alvarez-Larran A., Rodriguez L., Casado M., Gallur L., Giraldo P., Hernandez R., Menor D., Rodriguez M.J., Caballero D., Gonzalez R., Mayans J., Millan I., Cabrera J.R. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients // Ann. Hematol. – 2006. – Vol. 85, N 6. – P. 400-406.

143

Taylor R.M., Bockenstedt P., Su G.L. Marrero J.A., Pellitier S.M., Fontana R.J. Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature // Liver Transpl. – 2006. – Vol. 12, N 5. – P. 781-791.

144

Parodi E., Nobili B., Perrotta S., Rosaria Matarese S.M., Russo G., Licciardello M., Zecca M., Locatelli F., Cesaro S., Bisogno G., Giordano P., De Mattia D., Ramenghia U. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment // Int. J. Hematol. – 2006. – Vol. 84, N 1. – P. 48-53.

145

Latifzadeh S.Z., Entezari V. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report // Clin. Appl. Thromb. Hemost. – 2006. – Vol. 12, N 4. – P. 489-492.

146

Wiestner, A., Cho H.J., Asch A.S., Michelis M.A., Zeller J.A., Peerschke E.I., Weksler B.B., Schechter G.P. Rituximab in the treatment of acquired factor VIII inhibitors // Blood. – 2002. – Vol. 100, N 9. – P. 3426-3428.

147

Kain S., Copeland T.S., LeahyM.F. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab) // Br. J. Haematol. – 2002. – Vol. 119, N 2. – P. 578.

148

Marietta M., Pozzi S., Luppi M., Bertesi M., Cappi C., Morselli M., Torelli G. Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman’s disease: a case report // Eur. J. Haematol. – 2003. – Vol. 70, N 3. – P. 181-182.

149

Stasi R., Brunetti M., Stipa E., Amadori S. Selective B-cell depl etion with rituximab for the treatment of patients with acquired hemophilia // Blood. – 2004. – Vol. 103, N 12. – P. 4424-4428.

150

Huang Y.W., Saidi P., Philipp C. Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases // Haemophilia. – 2004. – Vol. 10, N 6. – P. 713-721.

151

Holme P.A., Brosstad F., Tjonnfjord G.E. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies // Haemophilia. – 2005. – Vol. 11, N 5. – P. 510-515.

152

Abdallah A., Coghlan D.W., Duncan E.M., Chunilal S.D., Lloyd J.V. Rituximab-induced longterm remission in patients with refractory acquired hemophilia // J. Thromb. Haemost. – 2005. – Vol. 3, N 11. – P. 2589-2590.

153

Berezne A., Stieltjes N., Le-Guern V., Teixeira L., Billy C., Roussel-Robert V., Flaujac C., Horellou M.H., Guillevin L., Mouthon L. Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases // Transfus. Med. – 2006. – Vol. 16, N 3. – P. 209-212.

154

Rojas-Garcia R., Gallardo E., de Andres I., de Luna N., Juarez C., Sanchez P., Illa I. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab // Neurology. – 2003. – Vol. 61, N 12. – P. 1814-1816.

155

Ruegg S.J., Fuhr P., Steck A.J. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg // Neurology. – 2004. – Vol. 63, N 11. – P. 2178-2179.

156

Goldfarb A.R., Weimer L.H., Brannagan, 3rd T.H. Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy // Muscle Nerve. – 2005. – Vol. 31, N 4. – P. 510-515.

157

Broglio L., Lauria G. Worsening after rituximab treatment in anti-mag neuropathy // Muscle Nerve. – 2005. – Vol. 32, N 3. – P. 378-379.

158

Kilidireas C., Anagnostopoulos A., Karandreas N., Mouselimi L., Dimopoulos M.A. Rituximab therapy in monoclonal IgM-related neuropathies // Leuk. Lymphoma. – 2006. – Vol. 47, N 5. – P. 859-864.

159

Kelly J.J. Chronic peripheral neuropathy responsive to rituximab // Rev. Neurol. Dis. – 2006. – Vol. 3, N 2. – P. 78-81.

160

Gorson K.C., Natarajan N., Ropper A.H., Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial // Muscle Nerve. – 2007. – Vol. 35, N 1. – P. 66-69.

161

Zaja F., Russo D., Fuga G., Perella G., Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant // Neurology. – 2000. – Vol. 55, N 7. – P. 1062-1063.

162

Wylam M.E., Anderson P.M., Kuntz N.L., Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report // J. Pediatr. – 2003. – Vol. 143, N 5. – P. 674-677.

163

Gajra A., Vajpayee N., Grethlein S.J. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma // Am. J. Hematol. – 2004. – Vol. 77, N 2. – P. 196-197.

164

Takagi K., Yoshida A., Iwasaki H., Inoue H., Ueda T. Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma // Ann. Hematol. – 2005. – Vol. 84, N 8. – P. 548-550.

165

Hain B., Jordan K., Deschauer M., Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab // Muscle Nerve. – 2006. – Vol. 33, N 4. – P. 575-580.

166

Borradori L., Lombardi T., Samson J., Girardet C., Saurat J.H., Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus // Arch. Dermatol. – 2001. – Vol. 137, N 3. – P. 269-272.

167

Salopek T.G., Logsetty S., Tredget E.E. Anti-CD20 chimeric monoclonal anti-body (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder // J. Am. Acad. Dermatol. – 2002. – Vol. 47, N 5. – P. 785-788.

168

Herrmann G., Hunzelmann N., Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab) // Br. J. Dermatol. – 2003. – Vol. 148, N 3. – P. 602-603.

169

Cooper H.L., Healy E., Theaker J.M., Friedmann P.S. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab) // Clin. Exp. Dermatol. – 2003. – Vol. 28, N 4. – P. 366-368.

170

Goebeler M., Herzog S., Brocker E.B., Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab // Br. J. Dermatol. – 2003. – Vol. 149, N 4. – P. 899-901.

171

Dupuy A., Viguier M., Bedane C., Cordoliani F., Blaise S., Aucouturier F., Bonnetblanc J.M., Morel P., Dubertret L., Bachelez H. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody) // Arch. Dermatol. – 2004. – Vol. 140, N 1. – P. 91-96.

172

Espana A., Fernandez-Galar M., Lloret P., Sanchez-Ibarrola A., Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations // J. Am. Acad. Dermatol. – 2004. – Vol. 50, N 6. – P. 974-976.

173

Morrison L.H. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab) // J. Am. Acad. Dermatol. – 2004. – Vol. 51, N 5. – P. 817-819.

174

Wenzel J., Bauer R., Bieber T., Tuting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants // Acta Derm. Venereol. – 2005. – Vol. 85, N 2. – P. 185-186.

175

Arin M.J., Engert A., Krieg T., Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus // Br. J. Dermatol. – 2005. – Vol. 153, N 3. – P. 620-625.

176

Kong H.H., Prose N.S., Ware R.E., Hall, 3rd, R.P. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab) // Pediatr. Dermatol. – 2005. – Vol. 22, N 5. – P. 461-464.

177

Cecchi R., Gasperini U. Severe pemphigus vulgaris treated with rituximab (Mabthera). J. Dermatol. – 2005. – Vol. 32, N 10. – P. 862-864.

178

Esposito M., Capriotti E., Giunta A., Bianchi L., Chimenti S. Long-lasting remission of pemphigus vulgaris treated with rituximab // Acta Derm. Venereol. – 2006. – Vol. 86, N 1. – P. 87-89.

179

Niedermeier A., Worl P., Barth S., Schuler G., Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment // Eur. J. Dermatol. – 2006. – Vol. 16, N 3. – P. 266-270.

180

Borel C., Launay F., Garrouste C., Astudillo L., Bazex J., Arlet P., Paul C., Viraben R., Sailler L. Rituximab induced remission of pemphigus vulgaris: 2 cases // Rev. Med. Interne, 2006.

181

Ahmed A.R., Spigelman Z., Cavacini L.A., Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin // N. Engl. J. Med. – 2006. – Vol. 355, N 17. – P. 1772-1779.

182

Salvi M., Vannucchi G., Campi I., Rossi S., Bonara P., Sbrozzi F., Guastella C., Avignone S., Pirola G., Ratiglia R., Beck-Peccoz P. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression // Eur. J. Endocrinol. – 2006. – Vol. 154, N 4. – P. 511-517.

183

Saigal K., Valencia I.C., Cohen J., Kerdel F.A. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab // J. Am. Acad. Dermatol. – 2003. – Vol. 49, N 5, Suppl. – P. S283-S285.

184

Levi M., Hack C.E., van Oers M.H. Rituximabinduced elimination of acquired angioedema due to C1-inhibitor deficiency // Am. J. Med. – 2006. – Vol. 119, N 8. – P. e3-e5.

185

Ratanatharathorn V., Ayash L., Reynolds C., Silver S., Reddy P., Becker M., Ferrara J.L., Uberti J.P. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody // Biol. Blood Marrow Transplant. – 2003. – Vol. 9, N 8. – P. 505-511.

186

Okamoto M., Okano A., Akamatsu S., Ashihara E., Inaba T., Takenaka H., Katoh N., Kishimoto S., Shimazaki C. Rituximab is effective for steroid-refractory sclerodermatous chronic graftversus-host disease // Leukemia. – 2006. 20, N 1. – P. 172-173.

187

Cutler C., Miklos D., Kim H.T., Treister N., Woo S.B., Bienfang D., Klickstein L.B., Levin J., Miller K., Reynolds C., Macdonell R., Pasek M., Lee S.J., Ho V., Soiffer R., Antin J.H., Ritz J., Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease // Blood. – 2006. 108, N 2. – P. 756-762.

The authors declare that there are no conflicts of interest present.